A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells
Clinical trial NCT00000822 · COMPLETED
Trial details
- NCT number
- NCT00000822
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.